Like a lot of biotechs, Juno Therapeutics ($JUNO) has seen its share price kicked down to what would have looked like a bargain-basement rate from its highs in 2015 as a bear market mauled industry valuations in recent weeks.
But that hasn't stopped the high-profile CAR-T player from being generous with its two top executives.
According to a recent SEC filing, CEO Hans Bishop got a bonus bonus of $148,750, bringing his total to $425,000. And CFO Steven Harr nailed down an extra $112,000, bringing his bonus to $320,000 for 2015.
By any measure, 2015 was a big year for Bishop and Harr. Juno struck a $1 billion collaboration deal with Celgene ($CELG), which paid $93 a share to grab more than 9 million shares and position itself as a close partner in the development of personalized CAR-T drugs to fight cancer, equipping T cells with a chimeric antigen receptor to target cancer cells.
Juno's share price has been rapidly melting away, though, right along with the Nasdaq biotech index. The company's shares were still selling for more than $56 in November. This morning, the stock was trading at less than $27 a share.
- here's the SEC filing